In a historic leap for Indian medical science, the country has officially launched NexCAR19, its first indigenous CAR T-cell therapy, offering new hope to patients battling severe blood cancers such as leukemia and lymphoma. The breakthrough marks a defining moment for India’s healthcare innovation and biotechnology capabilities.
Developed by ImmunoACT in collaboration with IIT Bombay and Tata Memorial Hospital, NexCAR19 is a cutting-edge therapy that works by genetically reprogramming a patient’s own immune cells to identify and destroy cancer cells. This personalized treatment has shown remarkable success worldwide, but until now, remained prohibitively expensive and largely inaccessible in India.
With NexCAR19, India becomes one of the few countries to develop its own CAR T-cell platform—dramatically increasing affordability and accessibility for Indian patients. The therapy is expected to be significantly more cost-effective than international alternatives, making advanced cancer care reachable for thousands who previously had limited options.
Health experts and researchers have hailed the launch as a transformative milestone, placing India firmly on the global map of advanced cancer treatment and reaffirming the nation’s commitment to cutting-edge, patient-centric innovation.
A proud moment for Indian science, and a new dawn of hope for cancer patients across the country.
